The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide (an anticholinergic ) and salbutamol sulfate (albuterol sulfate, a β 2 -adrenergic receptor agonist ) used in the management of chronic obstructive pulmonary disease (COPD) and asthma .  It is marketed by Boehringer Ingelheim as a metered dose inhaler (MDI) and nebuliser under the trade name Combivent . It is also marketed by Dey, . ( Napa , California ) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva. The chemical is sold in India by Cipla as duolin. 
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of albuterol inhalation aerosol (eg, Proair® HFA) in children 4 years of age and older, albuterol inhalation powder (eg, Proair® Respiclick®) in children 4 years of age and older, and albuterol inhalation solution (eg, Accuneb®) in children 2 years of age and older. However, safety and efficacy have not been established for the albuterol inhalation aerosol and albuterol inhalation powder in children younger than 4 years of age, and albuterol inhalation solution in children younger than 2 years of age.